Roctavian first hemophilia gene therapy to gain federal price in Germany

California, USA-based biotech firm BioMarin Pharmaceutical (Nasdaq: BMRN) has announced an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement amount for Roctavian (valoctocogene roxaparvovec-rvox) for people with severe hemophilia A.

BioMarin noted that this is the first gene therapy for hemophilia to receive an agreed federal price in Germany.

"We are pleased to have reached an agreement on the reimbursement amount for Roctavian with the GKV-SV, which is responsible for health insurance that covers approximately 90% of the German population," said Jeff Ajer, executive vice president and chief commercial officer at BioMarin. "This important progress will facilitate access to Roctavian for eligible individuals among the roughly 2,000 adults with severe hemophilia A in Germany and marks a key step forward for the hemophilia community," he added.